All‐cause mortality · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in all‐cause mortality compared with continuation (low certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality (ticlopidine vs placebo) (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus placebo ( (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
Sildenafil citrate showed no clear difference in all‐cause mortality compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
Tadalafil showed no clear difference in all‐cause mortality compared with placebo or no therapy (low certainty).
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
1 finding from 1 review
All‐cause mortality · Adults with COPD
Statins showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · chronic hepatitis B
1 finding from 1 review
All‐cause mortality · people with hepatic encephalopathy
Flumazenil showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with non‐ST elevation acute coronary syndromes
Heparin showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · farmworkers, soldiers, and people in endemic areas
Summary of findings table ‐ Antibiotics showed no clear difference in all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review